Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Bolt Biotherapeutics ( (BOLT) ).
On June 6, 2025, Bolt Biotherapeutics implemented a one-for-twenty reverse stock split of its common stock, following approval from stockholders and the Board of Directors on May 27, 2025. This move affects the company’s outstanding shares, equity incentive plans, and stock options, with trading on a split-adjusted basis set to begin on June 9, 2025, on the Nasdaq Capital Market under the ticker ‘BOLT’.
The most recent analyst rating on (BOLT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Bolt Biotherapeutics stock, see the BOLT Stock Forecast page.
Spark’s Take on BOLT Stock
According to Spark, TipRanks’ AI Analyst, BOLT is a Neutral.
Bolt Biotherapeutics faces significant challenges in financial performance and valuation, with ongoing losses impacting its attractiveness to investors. The technical analysis shows bearish signals, suggesting weak market sentiment. Structural improvements are necessary for enhancing financial health and stock performance.
To see Spark’s full report on BOLT stock, click here.
More about Bolt Biotherapeutics
Bolt Biotherapeutics, Inc. operates in the biotechnology industry, focusing on developing immuno-oncology therapeutics.
Average Trading Volume: 334,724
Technical Sentiment Signal: Sell
Current Market Cap: $12.41M
See more insights into BOLT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue